Related Experiment Video
Updated: May 14, 2026
09:56
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
The Long and Winding Road To Biologic Follow-ons
Biotechnology Healthcare
|February 2, 2013
Summary
Follow-on biologics offer cheaper biopharmaceuticals but present complex scientific challenges. Regulation is evolving but lags behind scientific advancements in this area.
Area of Science:
- Biotechnology
- Pharmaceutical Science
- Regulatory Science
Background:
- Follow-on biologics (FOBs) are analogous to generics for traditional drugs but possess greater scientific complexity.
- The development of FOBs presents challenges due to intricate manufacturing processes and the nature of biological products.
- Existing regulatory frameworks, established for chemical generics, are not fully equipped to address the nuances of FOBs.
Purpose of the Study:
- To examine the current scientific and regulatory landscape of follow-on biologics.
- To highlight the complexities and challenges associated with the development and approval of FOBs.
- To discuss the evolving legal and scientific considerations for FOBs.
Main Methods:
- Review of current scientific literature on biologic drug development.
- Analysis of existing and proposed regulatory guidelines for follow-on biologics.
- Comparative assessment of challenges posed by FOBs versus traditional generics.
Main Results:
- FOBs involve scientific subtleties and complexities not present in traditional generics.
- The science of FOBs is advancing rapidly, outpacing regulatory adaptation.
- There is a significant gap between the scientific intricacies of FOBs and current regulatory frameworks.
Conclusions:
- The regulation of follow-on biologics remains unsettled due to scientific complexities.
- Advancements in biotechnology necessitate updated regulatory approaches for FOBs.
- Balancing accessibility of cheaper biopharmaceuticals with scientific rigor is a key challenge.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:28Biopharmaceutics and Pharmacokinetics: Overview
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...